The European Crohn’s and Colitis Organisation (ECCO) guidelines state that the use of anti-TNFα mAb can be detrimental to patients undergoing cancer treatment and should be avoided for 2 years (5 years for patients with a high risk of recurrence) after cancer treatment [3]. The gene discussed is TNF; the disease is cancer.